瑞普生物
(300119)
| 流通市值：58.50亿 | | | 总市值：80.31亿 |
| 流通股本：3.39亿 | | | 总股本：4.65亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,720,460,367.77 | 826,126,074.24 | 3,398,458,452.83 | 2,544,325,031.33 |
| 营业收入 | 1,720,460,367.77 | 826,126,074.24 | 3,398,458,452.83 | 2,544,325,031.33 |
| 二、营业总成本 | 1,487,878,552.08 | 704,661,498.03 | 3,020,087,411.56 | 2,202,944,319.05 |
| 营业成本 | 1,036,930,674.4 | 497,907,185.78 | 1,995,662,711.33 | 1,475,882,995 |
| 税金及附加 | 18,070,830.36 | 8,142,841.64 | 28,019,597.7 | 19,339,952.64 |
| 销售费用 | 207,372,707.67 | 96,171,383.81 | 503,814,789.02 | 366,424,397.96 |
| 管理费用 | 100,701,092.18 | 48,489,451.57 | 204,913,175.43 | 157,658,513.48 |
| 研发费用 | 107,352,173.23 | 45,325,880.26 | 253,019,299.62 | 157,025,388.67 |
| 财务费用 | 17,451,074.24 | 8,624,754.97 | 34,657,838.46 | 26,613,071.3 |
| 其中:利息费用 | 16,058,154.9 | 8,160,574.95 | 35,158,001.14 | 27,216,420.24 |
| 其中:利息收入 | 1,130,326.46 | 588,793.52 | 2,489,936.51 | 1,854,734.55 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 10,086,942.92 | 4,394,555.81 | 75,831,147.54 | 44,482,336.25 |
| 加:投资收益 | 6,666,382.23 | 9,058,766.74 | 34,221,849.5 | 59,907,276.57 |
| 资产处置收益 | 2,822.84 | - | 3,819,392.15 | 3,761,700.78 |
| 资产减值损失(新) | 21,895.03 | 21,895.03 | -6,845,074.75 | 373,473.73 |
| 信用减值损失(新) | -17,781,269.74 | -10,386,586.72 | -34,589,852.5 | -22,398,851.25 |
| 其他收益 | 8,480,297.25 | 4,051,948.12 | 28,776,416.74 | 14,765,085.85 |
| 四、营业利润 | 240,058,886.22 | 128,605,155.19 | 479,584,919.95 | 442,271,734.21 |
| 加:营业外收入 | 1,515,901.04 | 191,121.65 | 2,294,049.6 | 2,123,280.3 |
| 减:营业外支出 | 589,296.03 | 332,832.89 | 11,188,338.23 | 3,885,697.25 |
| 五、利润总额 | 240,985,491.23 | 128,463,443.95 | 470,690,631.32 | 440,509,317.26 |
| 减:所得税费用 | 19,070,251.43 | 11,054,602.15 | 36,221,382.29 | 49,717,760.09 |
| 六、净利润 | 221,915,239.8 | 117,408,841.8 | 434,469,249.03 | 390,791,557.17 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 221,915,239.8 | 117,408,841.8 | 434,469,249.03 | 390,791,557.17 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 204,105,426.38 | 107,778,219.26 | 400,513,483.64 | 362,307,052.9 |
| 少数股东损益 | 17,809,813.42 | 9,630,622.54 | 33,955,765.39 | 28,484,504.27 |
| 扣除非经常损益后的净利润 | 184,339,567.88 | 95,468,233.84 | 304,522,472.61 | 269,277,854.2 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.45 | 0.24 | 0.88 | 0.8 |
| (二)稀释每股收益 | 0.45 | 0.24 | 0.88 | 0.8 |
| 八、其他综合收益 | - | - | 45,528.73 | - |
| 归属于母公司股东的其他综合收益 | - | - | 45,528.73 | - |
| 九、综合收益总额 | 221,915,239.8 | 117,408,841.8 | 434,514,777.76 | 390,791,557.17 |
| 归属于母公司股东的综合收益总额 | 204,105,426.38 | 107,778,219.26 | 400,559,012.37 | 362,307,052.9 |
| 归属于少数股东的综合收益总额 | 17,809,813.42 | 9,630,622.54 | 33,955,765.39 | 28,484,504.27 |
| 公告日期 | 2026-08-26 | 2026-04-28 | 2026-03-31 | 2025-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |